Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Excellent Preclinical Data On Novel Type Of Intranasal H5N1 Influenza Vaccine
Studies performed in three animal models confirmed the safety and intensive immunogenicity of a new type of intranasal H5N1 influenza vaccine, according to the latest preclinical study data announced today by the Vienna based firm, Avir Green Hills Biotechnology. The study data was just published in PloS One, the Public Library of Science.
generic viagra online
Even At High Doses, Gadolinium-Based Contrast Agents Cannot By Themselves Cause Patients To Develop Nephrogenic Systemic Fibrosis
Even at very high doses, gadolinium-based contrast agents alone are not sufficient to cause nephrogenic systemic fibrosis (NSF) in patients with kidney problems, according to a study performed at the Mayo Clinic Florida, Jacksonville, FL. NSF is a rare and serious syndrome that leads to fibrosis of the skin, joints and even internal organs. Some research indicates NSF is caused by gadolinium-based contrast agents that are commonly used today during MR procedures.
News of the day
U.S. Doubles Annual Malawi HIV/AIDS Support To $45M
The U.S. government recently announced a commitment to double its support for Malawi"s efforts to fight HIV/AIDS to $45 million annually, Xinhua reports (Xinhua, 6/2).
Health Insurance

Inconclusive Research Links Glargine Insulin (Lantus) With Cancer

Diabetes UK has today cautioned that research claiming there is a link between certain insulins and some cancers is "inconclusive". Results of four studies looking at the risk of cancer largely in people with Type 2 diabetes treated with insulin, particularly glargine insulin (Lantus), were published in Diabetologia - the Journal of the European Association for the Study of Diabetes - last week. The studies were based in Germany, Sweden, Scotland and the UK. The data of around 300,000 people treated with insulin was reviewed in the studies, of which 34,392 were taking glargine insulin (Lantus) alone. The German study suggested there may be a small increased risk of cancer in those taking glargine as their only insulin; with the strongest link seeming to be with breast cancer in older people. This small increase in risk appeared in two of the other three studies and seemed to be more so in people on high doses. Sir Professor George Alberti, Chairman of Diabetes UK, said: "It should be stated firmly that the evidence in these studies is not conclusive and that there are limitations with the research. "People with diabetes who are using glargine insulin should continue to take their medication as prescribed. You will become very ill if you stop taking your insulin. If you are concerned about these findings then you should speak to your healthcare team about your anxieties before discontinuing any treatment." Diabetes UK


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009